Belpointe Asset Management’s Novo Nordisk NVO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
Sell
-21,951
Closed -$1.12M 1155
2025
Q4
$1.12M Buy
21,951
+3,761
+21% +$192K 0.04% 386
2025
Q3
$1.01M Buy
18,190
+4,573
+34% +$268K 0.04% 400
2025
Q2
$940K Buy
13,617
+3,028
+29% +$206K 0.04% 376
2025
Q1
$735K Buy
10,589
+5,193
+96% +$429K 0.04% 425
2024
Q4
$751K Sell
5,396
-5,938
-52% -$642K 0.05% 399
2024
Q3
$1.35M Buy
11,334
+8,249
+267% +$1.1M 0.08% 244
2024
Q2
$440K Buy
3,085
+119
+4% +$15.8K 0.03% 485
2024
Q1
$381K Buy
2,966
+702
+31% +$83.6K 0.03% 513
2023
Q4
$234K Buy
2,264
+32
+1% +$3.17K 0.02% 616
2023
Q3
$203K Sell
2,232
-1,234
-36% -$109K 0.02% 600
2023
Q2
$280K Sell
3,466
-4,116
-54% -$336K 0.03% 477
2023
Q1
$603K Buy
7,582
+1,270
+20% +$90.1K 0.03% 485
2022
Q4
$427K Sell
6,312
-58
-0.9% -$3.4K 0.03% 608
2022
Q3
$318K Buy
6,370
+3,212
+102% +$172K 0.02% 667
2022
Q2
$176K Buy
3,158
+840
+36% +$46.6K 0.01% 877
2022
Q1
$129K Buy
+2,318
New +$119K 0.01% 1100
2021
Q3
Sell
-2,640
Closed -$111K 1230
2021
Q2
$111K Buy
+2,640
New +$102K 0.01% 1085

Other funds holding NVO

Belpointe Asset Management's NVO Position: Q1 2026 in Review

Belpointe Asset Management sold out of Novo Nordisk (NVO) in Q1 2026, closing a stake of 21,951 shares — an estimated $1.12M sold.

Belpointe Asset Management first reported a position in NVO in Q2 2021 and held it in 17 quarters. The position peaked at $1.35M in Q3 2024. 1,273 funds tracked by Wall St. Rank hold NVO as of Q1 2026.

  • Belpointe Asset Management reported no remaining Novo Nordisk position as of Q1 2026 after selling out during the quarter.
  • Belpointe Asset Management sold 21,951 Novo Nordisk shares in Q1 2026, an estimated $1.12M.
  • Belpointe Asset Management first reported a position in Novo Nordisk in Q2 2021 and held it in 17 quarters.
  • Belpointe Asset Management's Novo Nordisk position peaked at $1.35M in Q3 2024.
  • 1,273 funds tracked by Wall St. Rank held Novo Nordisk as of Q1 2026.

Based on Belpointe Asset Management's 13F filing for Q1 2026, filed 28 Apr 2026.